Treats primary hyperoxaluria type 1 (PH1). Sold as Oxlumo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Lumasiran Sodium (sold as Oxlumo), first approved Nov 23, 2020, with 1 new use approved and 0 published complete response letters.
| Oxlumo | Part D | $11.0M | +73% | 17 |
| Oxlumo | Part B | $3.2M | -12% | 0 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 23, 2020 | OxlumoNDA 214103 · New molecular entity | Alnylam Pharms Inc | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
